Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Update highlights platform evolution including RF sensing activation, SaverOne transaction, exploratory Liberia offshore initiative, Israeli subsidiary formation, and expansion into global defense and ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to ...
Northwestern Medicine investigators have uncovered a missing link behind the harmful effects of autoantibodies linked to ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at ...
Expands AI-Driven Infrastructure Powering Evidence-Based Patient Activation Across Enterprise Healthcare SAN DIEGO and BIRMINGHAM, Ala., March 25, 2026 /PRNewswire/ -- Guideway Care today announced ...
Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
Hay fever sufferers have attempted various treatments and techniques. They have tried antihistamines, nasal sprays, air ...
Enrollment spans Europe, the US, and Canada, targeting ~324 GA patients in a randomized, double-masked, sham-controlled phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results